IONIS PHARMACEUTICALS INC 4

Insider Michael R. Hayden indirectly purchased 20,000 shares of Ionis Pharmaceuticals, Inc. common stock over July 30–31, 2026, via his spouse’s entity at weighted average prices of about $53.38 and $51.60 per share.

On July 30 and 31, 2026, reporting person Michael R. Hayden, through his spouse and Genworks 2 Consulting, Inc., acquired a total of 20,000 shares of Ionis Pharmaceuticals, Inc. common stock in open-market purchases at weighted average prices of $53.38 and $51.60 per share, respectively. The July 30 purchase was for 15,000 shares, increasing indirect holdings by spouse to 19,000 shares, and the July 31 purchase was for 5,000 shares, raising that indirect position to 24,000 shares. After these transactions, Hayden’s total direct and indirect ownership reported on the form is 54,298 shares of common stock. The purchases were executed in multiple trades within stated price ranges, and the filer has agreed to provide detailed trade breakdowns upon request, underscoring these as deliberate insider open-market buys rather than routine equity compensation events.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

fda

Accession

0000874015-26-000254

Alert Tier

7